Attacking The Flu Bug The Pharmacist s s Pro-Active Role in Preventing & Treating Influenza

Transcription

1 Attacking The Flu Bug The Pharmacist s s Pro-Active Role in Preventing & Treating Influenza Catherine E. Cooke, PharmD, BCPS, PAHM This program has been brought to you by PharmCon

2 Attacking The Flu Bug The Pharmacist s s Pro-Active Role in Preventing & Treating Influenza Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed a specialty residency in Ambulatory Care/Managed Care through the Philadelphia College of Pharmacy and Science. After post-graduate training, Dr. Cooke served as a full-time Assistant Professor at the University of Maryland School of Pharmacy where she became a Board Certified Pharmacotherapy Specialist. Currently, she is an Independent Consultant working in health care quality and research. In addition, she provides clinical pharmacy services such as hypertension, dyslipidemia and smoking cessation management to patients in Maryland. Her main research interests are in the areas of cardiovascular pharmacotherapeutics and pharmacy services in the managed care environment with specific interest in discrepancies in health care based on sex or ethnicity. Speaker Disclosure: Dr. Cooke has no actual or potential conflicts of interest in relation to this program. This program has been brought to you by PharmCon PharmCon is accredited by the accreditation counsel for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

3 Attacking The Flu Bug The Pharmacist s s Pro-Active Role in Preventing & Treating Influenza Accreditation: Pharmacists L01-P Technicians L01-T Target Audience: Pharmacists & Technicians CE Credits: 1.0 Credit hour or 0.1 CEU for pharmacists/technicians Expiration Date: 9/17/2011 Program Overview: Pharmacists can play a pro-active role in the treatment of influenza and must understand the various delivery options. This program for pharmacists will enhance their knowledge about the flu and currently available vaccine delivery options and information needed to educate and treat patients. Objectives: 1.Describe the signs, symptoms, and diagnosis of current strains of influenza, distinguishing flu from the common cold. 2. Review the various pharmaceutical options for the prevention and treatment of influenza to include ease of use, comparative efficacy, pharmacokinetics and contraindications of vaccines. 3. Explain the pharmacist s role in the prevention and treatment of Influenza. This program has been brought to you by PharmCon

4 Learning Objectives DESCRIBE the signs, symptoms, and diagnosis of current strains of o influenza, distinguishing flu from the common cold REVIEW the various pharmaceutical options for the prevention and treatment of influenza EXPLAIN the pharmacist s s role in the prevention and treatment of Influenza Reference: Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NS; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep Aug 8;57(RR- 7):1-60.

5 Flu prevention Strategies Wash your hands Scrub hands vigorously for at least 15 seconds, rinse well and turn off the faucet with a paper towel. OR Use 60% alcohol-based hand gel Eat right, sleep tight Fresh fruits and vegetables, whole grains, and small amounts of lean protein Adults hours/night Older children and teens 9-10 hours/night Exercise regularly Avoid crowds during flu season

6 Human Influenza Contagious respiratory illness caused by influenza virus Yearly winter epidemics Peak activity usually in January and February Sporadic, unpredictable pandemics

7 Influenza Virus Type of nuclear material Hemagglutinin Neuraminidase A/Fujian/411/2002 (H3N2) Virus type Geographic origin Strain number Year of isolation Virus subtype

8 Influenza Clinical Features Incubation period 2 days (range days) Common signs and symptoms of the flu: Fever over 101 F (38 C) in adults, and often as high as 103 to 105 F (39.5 C to 40.5 C) in children Chills and sweats Headache Dry cough Muscular aches and pains, especially in your back, arms and legs Fatigue and weakness Nasal congestion Loss of appetite Diarrhea and vomiting in children Severity of illness depends on prior experience with related variants

9 Influenza Complications Pneumonia Primary influenza viral Secondary bacterial Reye s s syndrome Myocarditis Death per 1,000 cases

10 Influenza-Associated Hospitalizations By Age Group (Thompson, JAMA, 2004) Hospitalizations Per 100,000 Person Years Yrs 5-49 Yrs Yrs > 65 Yrs Age Group

11 Influenza-Associated Deaths By Age Group, (Thompson, JAMA 2003) 120 R&C Deaths Per 100,000 Person Years < 1 Yrs 1-4 Yrs 5-49 Yrs Yrs 65+ Yrs Age Group

12 Influenza Diagnosis Clinical and epidemiological characteristics Isolation of influenza virus from clinical specimen (e.g., nasopharynx, throat, sputum) Significant rise in influenza IgG by serologic assay Direct antigen testing for type A virus

13 Month of Peak Influenza Activity United States, Percent % 19% 13% 13% 3% 3% Dec Jan Feb Mar Apr May MMWR 2007;55(RR-6):5

14 Preventing the Flu #1 Prevention Strategy Influenza Vaccines

15

16

17 Composition of the Influenza Vaccine* A/Brisbane/59/2007 (H1N1) A/Brisbane/10/2007 (H3N2) B/Florida/4/2006 *manufacturers may use strains that are antigenically identical to the selected strains

18 Influenza vaccination recommendations Adults 2008

19 Influenza vaccination recommendations Children and adolescents, 6 months to 18 years 2008

20 Inactivated flu vaccine IM injection

21 Inactivated Influenza Vaccine Efficacy 70%-90% effective among healthy persons younger than 65 years of age 30%-40% effective among frail elderly persons 50%-60% effective in preventing hospitalization 80% effective in preventing death

22 Influenza and Complications Among Nursing Home Residents Vaccinated* Unvaccinated Percent RR=1.9 Illness Percent RR=2.5 RR=2.0 RR=4.2 Hosp Pneu Death *Inactivated influenza vaccine. Genesee County, MI,

23 Inactivated Influenza Vaccine Schedule Age Group 6-35 mos 3-8 yrs >9 yrs Dose 0.25 ml 0.50 ml 0.50 ml No. Doses 1* or 2 1* or 2 1 *Only one dose is needed if the child received 2 doses of influenza vaccine during the previous influenza season

24 Influenza Vaccination of Children 6 Months Through 8 Years Of Age* Previous vaccination One dose last year Vaccine THIS year Two doses One dose in each of the last 2 years One dose 3 years ago One dose in each of the last 3 years One dose One dose One dose *children 9 years and older should receive only one dose of influenza vaccine per year regardless of the number of doses in previous years

25 Inactivated Influenza Vaccine Adverse Reactions Local reactions 15%-20% Fever, malaise not common Allergic reactions rare Neurological very rare reactions

26 Inactivated Influenza Vaccine Contraindications and Precautions Severe allergic reaction to a vaccine component (e.g., egg) or following a prior dose of vaccine Moderate or severe acute illness History of Guillian Barre syndrome within 6 weeks following a previous dose of TIV (precaution)

27 Percentage of children fully vaccinated (i.e., 1 or 2 doses as appropriate) against influenza among children months of age, IIS Sentinel Site Project, & influenza seasons Preliminary Data Fully vaccinated, Fully vaccinated, Percent (%) OR MI AZ IIS Sentinel Site *Note: OR sentinel site expanded from Washington County in through seasons to include Multnomah county in season. Michigan added one county to its sentinel site region in season.

28 Live attenuated vaccine (LAIV) intranasal administration

29 LAIV Efficacy in Healthy Children 87% effective against culture-confirmed confirmed influenza in children years old 27% reduction in febrile otitis media (OM) 28% reduction in OM with accompanying antibiotic use Decreased fever and OM in vaccine recipients who developed influenza

30 LAIV Efficacy in Healthy Adults 20% fewer severe febrile illness episodes 24% fewer febrile upper respiratory illness episodes 27% fewer lost work days due to febrile upper respiratory illness 18%-37% fewer days of healthcare provider visits due to febrile illness 41%-45% 45% fewer days of antibiotic use

31 Live Attenuated Influenza Vaccine Schedule Age Group 2-8 years, no previous influenza vaccine Number of Doses 2 (separated by 4 weeks) 2-8 years, previous influenza vaccine * 9-49 years 1 1 * LAIV or inactivated vaccine

32 Live Attenuated Influenza Vaccine Indications Healthy*, nonpregnant persons years of age healthy children healthcare personnel persons in close contact with high-risk groups persons who want to reduce their risk of influenza *Persons who do not have medical conditions that increase their risk for complications of influenza

33 Live Attenuated Influenza Vaccine Adverse Reactions Children no significant increase in URI symptoms, fever, or other systemic symptoms significantly increased risk of asthma or reactive airways disease in children months of age Adults significantly increased rate of cough, runny nose, nasal congestion, sore throat, and chills reported among vaccine recipients no increase in the occurrence of fever No serious adverse reactions identified

34 Live Attenuated Influenza Vaccine Contraindications and Precautions Children < 2 years* Persons > 50 years* Persons with chronic medical conditions* Children and adolescents receiving long- term aspirin therapy* *These persons should receive inactivated influenza vaccine

35 Live Attenuated Influenza Vaccine Contraindications and Precautions cont. Immunosuppression from any cause* Pregnant women* Severe (anaphylactic) allergy to egg or other vaccine components History of Guillain-Barr Barré syndrome Children < 5 years w/ recurrent wheezing* Moderate or severe acute illness *These persons should receive inactivated influenza vaccine

36 Influenza Vaccine Storage and Handling Both types of influenza vaccine must be stored at refrigerator temperature (35-46 F, 2-8 C) 2 Neither vaccine should be frozen If LAIV is inadvertently frozen the vaccine should be placed at refrigerator temperature and used as soon as possible

37 Antiviral Medication Recommendations

38 Influenza Antiviral Medications Two classes Adamantanes rimatadine and amantadine Currently not recommended for use due to high level of resistance among circulating influenza A viruses Neuraminidase inhibitors Oseltamivir and zanamivir Used for both prevention and for treatment

39

40

41 Neuraminidase Inhibitors Oseltamivir (Tamiflu - Roche) and Zanamivir (Relenza - GSK) Used for the treatment and prevention of seasonal influenza A and B virus infections Treatment should begin as soon as possible after symptom onset Ideally within first 2 days of illness 41

42 Neuraminidase Inhibitors Reduces duration of influenza symptoms by average of days when administered within 2 days of illness onset Recent observational study by McGeer, et al showed benefit even when treatment started >48 hours after onset* Reduces lower respiratory tract complications, pneumonia, and hospitalization in some studies McGeer study also suggests oseltamivir reduces mortality among hospitalized patients with lab- confirmed seasonal influenza A* Effective in preventing seasonal influenza 70-90% effectiveness when started within 48 hours of exposure in RCT *McGeer et al. Clin Infect Dis 2007

43 Oseltamivir - Tamiflu Available as a capsule or suspension administered by mouth Approved in the U.S. for treatment or prevention of influenza in persons aged 1 year Treatment for 5 days Prevention regimen typically for 10 days after exposure Pediatric dosage depends on age and weight For treatment of seasonal influenza, administered BID x 5 days Side effects: nausea, vomiting in some persons Reports of delirium in pediatric patients (adolescents, most reports from from Japan) Warning added to label in 2007

44 Zanamivir - Relenza Orally inhaled powder administered by mouth via special device Approved in the U.S. for Treatment of seasonal influenza (aged > 7 years) Prevention of seasonal influenza (aged > 5 years) Treatment dosage: two puffs in the morning and two at night for 5 days Prevention dosage: 2 puffs QD (typically for 10 days after exposure) Side effects Wheezing, and breathing problems Precautions Persons with chronic respiratory disease Pregnant women Resistance rare

45 Improving Vaccination Rates

46 Coverage Level (%) Self-Reported Influenza Vaccination Coverage Levels Among Selected Priority U.S. Adult Populations, *, National Health Interview Survey Source: CDC, NHIS. *Preliminary data from influenza season Year * >=65 yrs Healthy yrs Pregnant women Health-care workers Vaccine shortage: season

47 Conclusions Influenza causes substantial morbidity and mortality yearly in US Recommended annually for persons 6 months through 18 years > 50 years with high risk conditions Close contact with high risk Household members Health care workers

48 Conclusions Vaccine is primary prevention tool Live, intranasal spray vaccine for healthy persons 2-49 years No asthma or recurrent wheezing in year olds Inactivated, injectable vaccine for persons 6 months and older Oseltamivir and zanamivir are currently recommended influenza antiviral medications

49 Resources for Vaccines and Immunizations Local County Health Department CDC: Telephone 800-CDC CDC-INFO Website

50 References Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NS; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep Aug 8;57(RR-7):1-60.